Want to see TMO full AI Analyst Report?
TMO Stock Chart & Stats
$568.26
-$4.06(-0.71%)
At close: 4:00 PM EDT
$568.26
-$4.06(-0.71%)
Day’s Range― - ―
52-Week Range$435.27 - $643.99
Previous CloseN/A
Volume2.94M
Average Volume (3M)2.19M
Market Cap
$232.67B
Enterprise Value$228.94K
Total Cash (Recent Filing)$4.06B
Total Debt (Recent Filing)$42.55B
Price to Earnings (P/E)33.8
Beta0.69
Next Earnings
Oct 28, 2026EPS Estimate
6.41Next Dividend Ex-DateN/A
Dividend Yield0.29%
Share Statistics
EPS (TTM)18.62
Shares Outstanding369,747,280
10 Day Avg. Volume2,494,628
30 Day Avg. Volume2,192,417
Financial Highlights & Ratios
PEG Ratio4.54
Price to Book (P/B)4.08
Price to Sales (P/S)4.89
P/FCF Ratio34.62
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$617.35Price Target Upside8.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)25.11
Revenue Forecast (FY)$47.87B
Bulls Say, Bears Say
Bulls Say
Strong Free Cash Flow GenerationStrong operating cash flow and free cash flow support internal investment, acquisitions, dividends and buybacks while demonstrating solid earnings quality. Continued conversion should strengthen Thermo Fisher’s ability to fund growth without relying excessively on external capital.
Raised Growth And Margin OutlookThe raised outlook indicates improving demand and operating execution across the portfolio. Expected organic growth and margin expansion suggest productivity, volume leverage and commercial momentum can support earnings growth over the next several quarters.
Diversified, Recurring Life Sciences ModelThermo Fisher’s broad exposure across research, diagnostics and biopharma manufacturing reduces dependence on any single end market. Installed instruments generate follow-on consumables and service demand, while long customer relationships support durable recurring revenue.
Bears Say
Elevated Leverage And Financing CostsHigher leverage increases sensitivity to interest rates and slows financial flexibility for acquisitions, investment or shareholder returns. Ongoing interest expense can absorb a meaningful portion of operating gains if demand weakens or integration needs rise.
Profitability Below Prior PeaksAlthough current margins remain healthy, the decline from prior peaks indicates that mix, costs or normalization after earlier demand conditions have reduced profitability. Sustained recovery depends on productivity and volume leverage offsetting these pressures.
Muted Academic, Government And China DemandWeakness in research funding and China can restrain instrument and consumables demand across important customer groups. If recovery remains uneven, the company may face slower organic growth and less operating leverage despite strength in other segments.
Thermo Fisher News
TMO FAQ
What was Thermo Fisher Scientific’s price range in the past 12 months?
Thermo Fisher Scientific lowest stock price was $435.27 and its highest was $643.99 in the past 12 months.
What is Thermo Fisher Scientific’s market cap?
Thermo Fisher Scientific’s market cap is $232.67B.
When is Thermo Fisher Scientific’s upcoming earnings report date?
Thermo Fisher Scientific’s upcoming earnings report date is Oct 28, 2026 which is in 65 days.
How were Thermo Fisher Scientific’s earnings last quarter?
Thermo Fisher Scientific released its earnings results on Jul 23, 2026. The company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.719 by $0.311.
Is Thermo Fisher Scientific overvalued?
According to Wall Street analysts Thermo Fisher Scientific’s price is currently Undervalued.
Does Thermo Fisher Scientific pay dividends?
Thermo Fisher Scientific pays a Quarterly dividend of $0.47 which represents an annual dividend yield of 0.29%. See more information on Thermo Fisher Scientific dividends here
What is Thermo Fisher Scientific’s EPS estimate?
Thermo Fisher Scientific’s EPS estimate is 6.41.
How many shares outstanding does Thermo Fisher Scientific have?
Thermo Fisher Scientific has 369,747,280 shares outstanding.
What happened to Thermo Fisher Scientific’s price movement after its last earnings report?
Thermo Fisher Scientific reported an EPS of $6.03 in its last earnings report, beating expectations of $5.719. Following the earnings report the stock price went up 8.711%.
Which hedge fund is a major shareholder of Thermo Fisher Scientific?
Currently, no hedge funds are holding shares in TMO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Thermo Fisher Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$617.35 (8.64% Upside)
$617.35 (8.64% Upside)
Blogger Sentiment
Bullish
TMO Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.40%
12-Months-Change
Fundamentals
Return on Equity
0.29%
Trailing 12-Months
Asset Growth
11.80%
Trailing 12-Months
Company Description
Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
TMO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational execution: double-digit reported revenue growth, a clean beat to prior guidance, margin expansion, robust free cash flow, successful acquisition integration, numerous product launches and an upward revision to full-year guidance. The primary negatives were modest and manageable: the planned microbiology divestiture (small near-term revenue and EPS drag and future dilution), lingering softness in certain end markets (academic/government and parts of China), some unfavorable product mix impacts, a reduced FX tailwind and elevated leverage. Overall, the positives in the quarter — including beats, guidance raise, margin expansion and strong cash generation — substantially outweigh the lowlights.View all TMO earnings summariesTMO Revenue Breakdown
54.01% Laboratory Products and Biopharma Services
22.46% Life Sciences Solutions
17.40% Analytical Instruments
10.52% Specialty Diagnostics

TMO Stock 12 Month Forecast
Average Price Target
$617.35
▲(8.64% Upside)
Technical Analysis
Ownership Overview
0.13% Insiders
24.31% Mutual Funds
25.82% Other Institutional Investors
28.68% Public Companies and Individual Investors











